ATE496628T1 - Verwendung von lecithin als arzneimittel zur behandlung von psoriasis - Google Patents

Verwendung von lecithin als arzneimittel zur behandlung von psoriasis

Info

Publication number
ATE496628T1
ATE496628T1 AT06743672T AT06743672T ATE496628T1 AT E496628 T1 ATE496628 T1 AT E496628T1 AT 06743672 T AT06743672 T AT 06743672T AT 06743672 T AT06743672 T AT 06743672T AT E496628 T1 ATE496628 T1 AT E496628T1
Authority
AT
Austria
Prior art keywords
lecithin
treat psoriasis
medicine
marine
composition
Prior art date
Application number
AT06743672T
Other languages
English (en)
Inventor
Paul Dupont
Original Assignee
Sc Dicophar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sc Dicophar filed Critical Sc Dicophar
Priority claimed from PCT/FR2006/000792 external-priority patent/WO2006111633A2/fr
Application granted granted Critical
Publication of ATE496628T1 publication Critical patent/ATE496628T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06743672T 2005-04-18 2006-04-11 Verwendung von lecithin als arzneimittel zur behandlung von psoriasis ATE496628T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0503827A FR2884425B3 (fr) 2005-04-18 2005-04-18 Composition pharmaceutique destinee a soigner le psoriasis
FR0506496A FR2884423B1 (fr) 2005-04-18 2005-06-27 Utilisation de la lecithine comme medicament dans le traitement du psoriasis
PCT/FR2006/000792 WO2006111633A2 (fr) 2005-04-18 2006-04-11 Utilisation de la lecithine comme medicament dans le traitement du psoriasis

Publications (1)

Publication Number Publication Date
ATE496628T1 true ATE496628T1 (de) 2011-02-15

Family

ID=35463696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06743672T ATE496628T1 (de) 2005-04-18 2006-04-11 Verwendung von lecithin als arzneimittel zur behandlung von psoriasis

Country Status (4)

Country Link
AT (1) ATE496628T1 (de)
DE (1) DE602006019842D1 (de)
ES (1) ES2359987T3 (de)
FR (2) FR2884425B3 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108004016A (zh) * 2017-12-18 2018-05-08 青岛康境海洋生物科技有限公司 一种高卵磷脂含量的南极磷虾油的制备方法
CN113995763B (zh) * 2021-11-10 2023-08-11 中南大学湘雅医院 磷脂酰乙醇胺作为活性成分在制备银屑病治疗药物中的应用、银屑病治疗药物及其制备方法
FR3171583A1 (fr) * 2025-01-25 2026-07-31 Sc Dicophar Utilisation de phospholipides estérifiés par des acides gras polyinsaturés oméga-3 DHA comme médicament dans le traitement du psoriasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042348A1 (en) * 1997-03-25 1998-10-01 Wilson Trafton Crandall Topical moisturizing composition and method
US20020012648A1 (en) * 1998-02-06 2002-01-31 Orthoefer Frank T. High phospholipid-containing dermatological compositions
WO2005002591A1 (en) * 2003-07-02 2005-01-13 Fouad Abdelaziz Ahmed Hassanin Treatment psoriasis, impetigo, tinea by lipositol, cephalin and lecithin

Also Published As

Publication number Publication date
FR2884423B1 (fr) 2007-06-22
FR2884423A1 (fr) 2006-10-20
FR2884425A1 (fr) 2006-10-20
DE602006019842D1 (de) 2011-03-10
FR2884425B3 (fr) 2007-05-25
ES2359987T3 (es) 2011-05-30

Similar Documents

Publication Publication Date Title
Han et al. Anti-photoaging effect of hydrolysates from pacific whiting skin via MAPK/AP-1, NF-κB, TGF-β/Smad, and Nrf-2/HO-1 signaling pathway in UVB-induced human dermal fibroblasts
Dong et al. Age associated decrease of MT-1 melatonin receptor in human dermal skin fibroblasts impairs protection against UV-induced DNA damage
Măgerușan et al. A comprehensive bibliographic review concerning the efficacy of organic acids for chemical peels treating acne vulgaris
EA200802204A1 (ru) Применение ингибиторов dpp iv
PE20050255A1 (es) Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
Karimi et al. Aquaporin channels in skin physiology and aging pathophysiology: investigating their role in skin function and the hallmarks of aging
ATE489935T1 (de) Verwendung von glycyrrhetinsäure und/oder glycyrrhizin zur herstellung von zubereitungen zur bräunung der haut
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
ATE495728T1 (de) Kosmetische oder dermatologische zubereitungen mit n-acetylcystein
Kang et al. UP256 inhibits hyperpigmentation by tyrosinase expression/dendrite formation via rho-dependent signaling and by primary cilium formation in melanocytes
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
Bellavite et al. Skin photoaging and the biological mechanism of the protective effects of hesperidin and derived molecules
Fernando et al. (−)-Loliolide isolated from Sargassum horneri abate UVB-induced oxidative damage in human dermal fibroblasts and subside ECM degradation
Joyjamras et al. Recycled sericin hydrolysates modified by Alcalase® suppress melanogenesis in human melanin-producing cells via modulating MITF
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
Ma et al. Progress in research on animal collagen peptides: preparation, bioactivity, and application
Merlino et al. Recent progress in keloid mechanism and treatment: A comprehensive review
Kim et al. Prevention of UVB-induced photoaging by an ethyl acetate fraction from Allomyrina dichotoma larvae and its potential mechanisms in human dermal fibroblasts
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
Yeom et al. The alleviating effect of Lagerstroemia indica flower extract on stretch marks through regulation of mast cells
Kim Comparison of polynucleotide and polydeoxyribonucleotide in dermatology: Molecular mechanisms and clinical perspectives
Boothe et al. Radiation induced skin fibrosis (RISF): opportunity for angiotensin II-dependent intervention
ATE553760T1 (de) Verwendung von alverin zur behandlung von hauterkrankungen
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties